Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories
NCT07263074 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2026-03-30
Summary
This is a two-arm pilot randomized trial that assesses the feasibility and preliminary efficacy of a digital story and values clarification intervention (Considering alloHCT: Opportunities for Patient Reflection During Decision-Making via Digital Stories \[CHORDS\]) compared to usual care among patients with myeloid cancers considering allogeneic hematopoietic cell transplantation (alloHCT).
Conditions
- Myeloid Malignancy
Interventions
- OTHER
-
CHORDS
The CHORDS intervention consists of 1) digital stories created by individuals who previously underwent consultation for alloHCT and 2) explicit values clarification exercises designed to help patients reflect on their emotions and clarify what matters to them, including a) an interactive workbook, and b) best-worst scaling (BWS).
Sponsors & Collaborators
-
University of Rochester
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-01-15
- Primary Completion
- 2028-06-30
- Completion
- 2028-06-30
Countries
- United States
Study Locations
More Related Trials
-
A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
NCT04745676 ·Status: COMPLETED ·Phase: NA
-
Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
NCT00322101 ·Status: COMPLETED ·Phase: PHASE3
-
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
NCT01929408 ·Status: COMPLETED
-
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
NCT03672539 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation
NCT00460447 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)
NCT00038805 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL
NCT07059156 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
NCT00077116 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
NCT04217356 ·Status: ACTIVE_NOT_RECRUITING
-
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
NCT06697600 ·Status: RECRUITING ·Phase: NA
-
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT00801489 ·Status: RECRUITING ·Phase: PHASE2
-
Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
NCT00037596 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
NCT00049517 ·Status: COMPLETED ·Phase: PHASE3
-
Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL
NCT03460522 ·Status: RECRUITING ·Phase: PHASE2
-
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
NCT00038831 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
NCT00044733 ·Status: COMPLETED ·Phase: PHASE2
-
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
NCT03286114 ·Status: TERMINATED ·Phase: PHASE1
-
Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy
NCT01235572 ·Status: COMPLETED ·Phase: PHASE2
-
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
NCT00553202 ·Status: COMPLETED ·Phase: PHASE2
-
Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS
NCT00195000 ·Status: COMPLETED ·Phase: PHASE2
-
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
NCT03856216 ·Status: TERMINATED ·Phase: PHASE2
-
A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia
NCT04822766 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Lenalidomide Plus Chemotherapy for AML
NCT01681537 ·Status: COMPLETED ·Phase: PHASE1
-
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
NCT05940961 ·Status: RECRUITING ·Phase: PHASE2
-
S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00109837 ·Status: COMPLETED ·Phase: PHASE2